Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000287743> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2000287743 endingPage "174" @default.
- W2000287743 startingPage "174" @default.
- W2000287743 abstract "Van de Laar FA, Lucassen PL, Akkermans RP, et al . Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003639. Q In patients with type 2 diabetes mellitus, are α glucosidase inhibitors effective for improving glycaemic control? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★★☆☆ ### ![Graphic][1]</img>Data sources: Medline (to April 2003), EMBASE/Excerpta Medica (to April 2003), the Cochrane Central Register of Controlled Trials (Issue 3, 2003), LILACS (to April 2003), databases of ongoing trials (all to April 2003), Current Contents (to December 2003), contacting experts and manufacturers, and bibliographies of relevant studies. ### ![Graphic][2]</img>Study selection and assessment: randomised controlled trials (RCTs) in any language with ⩾12 weeks’ duration that compared α glucosidase inhibitor monotherapy with any other intervention in patients with type 2 diabetes and included … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif" @default.
- W2000287743 created "2016-06-24" @default.
- W2000287743 creator A5041564697 @default.
- W2000287743 date "2005-12-01" @default.
- W2000287743 modified "2023-09-27" @default.
- W2000287743 title "Review: glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes" @default.
- W2000287743 cites W2029749250 @default.
- W2000287743 cites W2083342497 @default.
- W2000287743 cites W2100076167 @default.
- W2000287743 cites W2603785760 @default.
- W2000287743 doi "https://doi.org/10.1136/ebm.10.6.174" @default.
- W2000287743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16262223" @default.
- W2000287743 hasPublicationYear "2005" @default.
- W2000287743 type Work @default.
- W2000287743 sameAs 2000287743 @default.
- W2000287743 citedByCount "1" @default.
- W2000287743 crossrefType "journal-article" @default.
- W2000287743 hasAuthorship W2000287743A5041564697 @default.
- W2000287743 hasBestOaLocation W20002877431 @default.
- W2000287743 hasConcept C126322002 @default.
- W2000287743 hasConcept C134018914 @default.
- W2000287743 hasConcept C168563851 @default.
- W2000287743 hasConcept C17744445 @default.
- W2000287743 hasConcept C187212893 @default.
- W2000287743 hasConcept C199539241 @default.
- W2000287743 hasConcept C2777180221 @default.
- W2000287743 hasConcept C2779473830 @default.
- W2000287743 hasConcept C2910068830 @default.
- W2000287743 hasConcept C535046627 @default.
- W2000287743 hasConcept C555293320 @default.
- W2000287743 hasConcept C71924100 @default.
- W2000287743 hasConceptScore W2000287743C126322002 @default.
- W2000287743 hasConceptScore W2000287743C134018914 @default.
- W2000287743 hasConceptScore W2000287743C168563851 @default.
- W2000287743 hasConceptScore W2000287743C17744445 @default.
- W2000287743 hasConceptScore W2000287743C187212893 @default.
- W2000287743 hasConceptScore W2000287743C199539241 @default.
- W2000287743 hasConceptScore W2000287743C2777180221 @default.
- W2000287743 hasConceptScore W2000287743C2779473830 @default.
- W2000287743 hasConceptScore W2000287743C2910068830 @default.
- W2000287743 hasConceptScore W2000287743C535046627 @default.
- W2000287743 hasConceptScore W2000287743C555293320 @default.
- W2000287743 hasConceptScore W2000287743C71924100 @default.
- W2000287743 hasIssue "6" @default.
- W2000287743 hasLocation W20002877431 @default.
- W2000287743 hasLocation W20002877432 @default.
- W2000287743 hasOpenAccess W2000287743 @default.
- W2000287743 hasPrimaryLocation W20002877431 @default.
- W2000287743 hasRelatedWork W1563850031 @default.
- W2000287743 hasRelatedWork W2032287785 @default.
- W2000287743 hasRelatedWork W2094113608 @default.
- W2000287743 hasRelatedWork W2136047525 @default.
- W2000287743 hasRelatedWork W2233866314 @default.
- W2000287743 hasRelatedWork W2383009242 @default.
- W2000287743 hasRelatedWork W2415759662 @default.
- W2000287743 hasRelatedWork W3036934084 @default.
- W2000287743 hasRelatedWork W4256514411 @default.
- W2000287743 hasRelatedWork W88627568 @default.
- W2000287743 hasVolume "10" @default.
- W2000287743 isParatext "false" @default.
- W2000287743 isRetracted "false" @default.
- W2000287743 magId "2000287743" @default.
- W2000287743 workType "article" @default.
!["Van de Laar FA, Lucassen PL, Akkermans RP, et al . Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003639. Q In patients with type 2 diabetes mellitus, are α glucosidase inhibitors effective for improving glycaemic control? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Endocrine ★★★★★☆☆ ### ![Graphic][1]</img>Data sources: Medline (to April 2003), EMBASE/Excerpta Medica (to April 2003), the Cochrane Central Register of Controlled Trials (Issue 3, 2003), LILACS (to April 2003), databases of ongoing trials (all to April 2003), Current Contents (to December 2003), contacting experts and manufacturers, and bibliographies of relevant studies. ### ![Graphic][2]</img>Study selection and assessment: randomised controlled trials (RCTs) in any language with ⩾12 weeks’ duration that compared α glucosidase inhibitor monotherapy with any other intervention in patients with type 2 diabetes and included … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif"](?object=%22Van%20de%20Laar%20FA%2C%20Lucassen%20PL%2C%20Akkermans%20RP%2C%20et%20al%20.%20Alpha-glucosidase%20inhibitors%20for%20type%202%20diabetes%20mellitus.%20Cochrane%20Database%20Syst%20Rev%202005%3B(2)%3ACD003639.%20Q%20In%20patients%20with%20type%202%20diabetes%20mellitus%2C%20are%20%CE%B1%20glucosidase%20inhibitors%20effective%20for%20improving%20glycaemic%20control%3F%20Clinical%20impact%20ratings%20GP%2FFP%2FPrimary%20care%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%20IM%2FAmbulatory%20care%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%E2%98%86%20Endocrine%20%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%85%E2%98%86%E2%98%86%20%23%23%23%20!%5BGraphic%5D%5B1%5D%3C%2Fimg%3EData%20sources%3A%20Medline%20(to%20April%202003)%2C%20EMBASE%2FExcerpta%20Medica%20(to%20April%202003)%2C%20the%20Cochrane%20Central%20Register%20of%20Controlled%20Trials%20(Issue%203%2C%202003)%2C%20LILACS%20(to%20April%202003)%2C%20databases%20of%20ongoing%20trials%20(all%20to%20April%202003)%2C%20Current%20Contents%20(to%20December%202003)%2C%20contacting%20experts%20and%20manufacturers%2C%20and%20bibliographies%20of%20relevant%20studies.%20%23%23%23%20!%5BGraphic%5D%5B2%5D%3C%2Fimg%3EStudy%20selection%20and%20assessment%3A%20randomised%20controlled%20trials%20(RCTs)%20in%20any%20language%20with%20%E2%A9%BE12%20weeks%E2%80%99%20duration%20that%20compared%20%CE%B1%20glucosidase%20inhibitor%20monotherapy%20with%20any%20other%20intervention%20in%20patients%20with%20type%202%20diabetes%20and%20included%20%E2%80%A6%20%5B1%5D%3A%20%2Fembed%2Finline-graphic-1.gif%20%5B2%5D%3A%20%2Fembed%2Finline-graphic-2.gif%22){kind=link}